Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Farmington’s Azitra lands $14M funding round

A Farmington biotech working with genetic engineering and microbiome science to develop skin disease treatments said it has raised its largest money to date. Azitra...

| By Kelley Gipson

CaroGen wins AVIDIO immunotherapy patent

CaroGen reports that the United States Patent and Trademark Office has issued CaroGen’s first composition of matter patent for its Artificial Virus (AV) for Infectious Diseases...

| By Kelley Gipson

Achillion gets breakthrough status for danicopan

Achillion reports that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination with a C5 monoclonal antibody for patients with...

| By Kelley Gipson

UConn declares Bioscience Connecticut a success

It’s been more than nine years since state lawmakers approved borrowing more than $1 billion to build-up Connecticut’s bioscience stature. A newly issued report from...

| By Kelley Gipson

Alexion agreement targets mitochondrial disease

Alexion and Stealth BioTherapeutics Corp have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people...

| By Kelley Gipson

Alexion to acquire Achillion

Alexion and Achillion have announced that they have entered into a definitive agreement for Alexion to acquire Achillion. Achillion is a clinical-stage biopharmaceutical company focused...

| By Kelley Gipson

Jackson Laboratory receives funding re eyes, aging

The National Eye Institute has continued funding for The Jackson Laboratory‘s Eye Mutant Resource. Serious or disabling eye diseases affect many millions of people worldwide...

| By Kelley Gipson

UConn developing system for treating depression

University of Connecticut professor of computer science and engineering Bing Wang is the lead principal investigator on a new $1 million grant from the National...

| By Kelley Gipson

VentureClash finalists named for 10/17 showdown

Connecticut Innovations, Connecticut’s strategic venture capital arm, has announced the finalists for VentureClash, the $5 million global venture challenge. The 10 finalists will participate in a...

| By Kelley Gipson

Biohaven migraine treatment wins priority review

Biohaven said in a recent regulatory filing that the FDA has accepted its new drug application for treatment and prevention of migraine headaches. The filing...